EML4-ALK rearrangement was firstly identified by Togashi et al in 2012.[5] With the development of next-generation sequencing (NGS), more and more novel ALK fusion partners have been identified, such as KIF5B, STRN, KLC1, TPR, HIP1, DCTN1, LTBP1,GCC2, SEC31A.[2] Herein, we report a rare fusion of 3 genes leucine rich repeat neuronal 2(LRRN2), latent transforming growth factor β binding protein 1(LTBP1) and huntingtin interacting protein 1 (HIP1)-ALK fusion in a patient with NSCLC using NGS. Here, LRRN2 is linked to non-small cell lung carcinoma.